---
title: "Nucala (mepolizumab) in severe eosinophilic asthma: Pharmacology questions"
description: "Pharmacology questions on Nucala (mepolizumab) in severe eosinophilic asthma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism and Pharmacokinetics. Questions: How does Nucala work in asthma (mechanism of action)? How much does Nucala lower blood eosinophils in severe asthma? How long does Nucala stay in your system (half-life)? 3 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/pharmacology"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Nucala (mepolizumab) in severe eosinophilic asthma: Pharmacology questions

Manufacturer: GlaxoSmithKline  
Prescribing information: [Nucala](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF)

Pharmacology questions that apply to every indication of Nucala are on [Nucala (mepolizumab), all indications: Pharmacology](https://www.evicenter.com/medical-information/nucala/pharmacology).

## Mechanism

<a id="nucala-mechanism"></a>

### How does Nucala work in asthma (mechanism of action)?

> “Mepolizumab is an IL-5 antagonist (IgG1 kappa). IL-5 is the major cytokine responsible for the 
> growth and differentiation, recruitment, activation, and survival of eosinophils. Mepolizumab 
> binds to IL-5 with a dissociation constant of 100 pM, inhibiting the bioactivity of IL-5 by 
> blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil 
> cell surface.”

Source: [NUCALA: Prescribing information, page 16, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=16)

> “Mepolizumab, by inhibiting IL-5 signaling, reduces the production 
> and survival of eosinophils; however, the mechanism of mepolizumab action in asthma, 
> CRSwNP, COPD, EGPA, and HES has not been definitively established.”

Source: [NUCALA: Prescribing information, page 16, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=16)

> “The MOA of NUCALA in asthma has not been definitively established.”

Source: [NUCALA: SEA Eosinophils & MOA, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/eosinophils-moa/#:~:text=The%20MOA%20of%20NUCALA%20in%20asthma%20has%20not%20been%20definitively%20established.)

<a id="nucala-eosinophil-reduction"></a>

### How much does Nucala lower blood eosinophils in severe asthma?

> “Following subcutaneous administration of 
> mepolizumab 100 mg every 4 weeks for 32 weeks in adult and adolescent subjects with severe”

Source: [NUCALA: Prescribing information, page 16, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=16)

> “asthma (MENSA Trial), blood eosinophils were reduced to a geometric mean count of 
> 40 cells/mcL, which corresponds to a geometric mean reduction of 84% compared with placebo.”

Source: [NUCALA: Prescribing information, page 17, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=17)

> “The pharmacodynamic response (blood eosinophil reduction) was also evaluated in children 
> aged 6 to 11 years with severe asthma. Following subcutaneous administration of mepolizumab 
> 40 mg every 4 weeks for 52 weeks, blood eosinophils were reduced to a geometric mean count 
> of 48 cells/mcL. This corresponds to a geometric mean reduction from baseline of 85%. 
> The magnitude of reduction in adults, adolescents, and children with severe asthma was observed 
> within 4 weeks of treatment and was maintained throughout the treatment periods.”

Source: [NUCALA: Prescribing information, page 17, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=17)

Note: The first two passages are one sentence divided by a page break in the Prescribing Information.

## Pharmacokinetics

<a id="nucala-half-life"></a>

### How long does Nucala stay in your system (half-life)?

> “Following subcutaneous administration of mepolizumab in adult subjects with asthma, the mean 
> terminal half-life (t1/2) ranged from 16 to 22 days. The population apparent systemic clearance of 
> mepolizumab in adult and adolescent subjects with asthma is estimated to be 0.28 L/day for a 
> 70-kg individual.”

Source: [NUCALA: Prescribing information, page 18, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=18)

> “Following 100-mg subcutaneous administration in the upper arm of adult and adolescent subjects 
> with asthma, the bioavailability of mepolizumab was estimated to be approximately 80%. 
> Following repeat subcutaneous administration once every 4 weeks, there was approximately a 
> 2-fold accumulation at steady state.”

Source: [NUCALA: Prescribing information, page 18, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=18)

## Related pages
- [Medical information: Nucala (mepolizumab): Severe eosinophilic asthma](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma)
- [Indication](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/safety)
- [Specific populations](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/access-and-coverage)
